Navigation Links
RVX-208 Exploratory Study Illustrates Early Potential for Alzheimer's Disease
Date:11/10/2008

r's Consortium partners, has been designated by the National Institutes of Health as one of just 31 Alzheimer's disease Centers in the nation.

About Resverlogix Corp.

Resverlogix Corp. is a leading biotechnology company engaged in the development of novel therapies for important global medical markets with significant unmet needs. The NexVas(TM) PR program is the Company's primary focus which is to develop novel small molecules that enhance ApoA-I. These vital therapies address the grievous burden of atherosclerosis and other important diseases such as acute coronary syndrome, diabetes, Alzheimer's disease, Peripheral Artery Disease and other vascular disorders. The Company's secondary focus is TGF-Beta Shield(TM), a program that aims to address burgeoning grievous diseases, such as cancer and fibrosis. Resverlogix Corp. trades on the Toronto Stock Exchange (TSX:RVX). For further information please visit http://www.resverlogix.com.

This news release may contain certain forward-looking statements that reflect the current views and/or expectations of Resverlogix Corp. with respect to its performance, business and future events. Such statements are subject to a number of risks, uncertainties and assumptions. Actual results and events may vary significantly. The TSX Exchange does not accept responsibility for the adequacy or accuracy of this news release.


'/>"/>
SOURCE Resverlogix Corp.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related biology technology :

1. International Steering Committee for RVX-208 IVUS Trial Formed
2. Phase 1b/2a Program Commences for RVX-208
3. Industry Leaders Select Resverlogixs RVX-208
4. Dosing for RVX-208 Phase 1a Clinical Study Completed
5. FDA Grants Resverlogix Approval to Commence a Phase 1 Clinical Trial for RVX-208
6. Reverse Cholesterol Transport by RVX-208 a Small Molecule for ApoA-I Production Increase Presented at American Heart Association Scientific Meeting
7. deCODE Study Expands Clinical Utility of deCODE AF(TM) for Improving the Diagnosis of Atrial Fibrillation and Preventing Stroke
8. Interim Analysis of Top-Line Data From Phase II/III Study Shows Favorable Efficacy & Safety for Cortheras Relaxin in Acute Heart Failure
9. Genomic Health Announces Publication of a Study Demonstrating the Oncotype DX(R) Breast Cancer Assay Influences Chemotherapy Treatment Recommendation in 44 Percent of Patients Evaluated
10. New Study Shares Best Practices in Biopharma Public Relations
11. Study From the University of Texas M.D. Anderson Cancer Center Demonstrates That AHCC(R) is Safe in Combination With Most Chemotherapeutic Agents
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/20/2013)... , May 20, 2013  (PSHR) Pacific ... naturally based products across a broad range of ... has retained investor relations firm, BlueWater Advisory Group, ... return to trading process, and to direct the ... initiation. Matthew Mills ...
(Date:5/20/2013)... (PRWEB) May 20, 2013 With bed bugs' ... said that although bed bugs need to be eliminated, one ... not compromise a person's health. And so to help bed ... to get rid of bed bugs without using ... bed bug spray it called Bed Bug Bully. , According ...
(Date:5/20/2013)... , May 20, 2013   Flexion Therapeutics ... Frederick W. Driscoll to its management team ... 30 years of financial management experience with biotechnology and ... Mr. Driscoll was chief financial officer for Novavax (NASDAQ: ... that secured more than $250 million through a combination ...
(Date:5/20/2013)... (PRWEB) May 20, 2013 Researchers from the ... the connection between lower back pain, and the acne causing ... in the system the bacteria seek out oxygen deprived location ... in the spinal column, P.acnes has the ability to live ... , Fernando Perez, a spokesman for “ The best acne ...
Breaking Biology Technology:Pacific Shore Holdings Retains Investor Relations Firm 2New Non Pesticide Discovery on How to Get Rid of Bed Bugs Tipped by My Cleaning Products 2Flexion Therapeutics Names Frederick Driscoll Chief Financial Officer 2Adult Acne Treatment, Probiotic Action Shares New Insight How Treating Acne May Help Reduce Body Pain 2
... 20 Kosan Biosciences,Incorporated (Nasdaq: KOSN ) ... as Senior Vice President and Chief Medical Officer. ... development and registration of cancer,therapeutics and has had ... and clinical pharmacologist, most notably at Novartis. Dr. ...
... are making a considerable impact on many aspects ... Reaching for the human frontier, robotics is also ... emerging domains. Interacting, exploring, and working with humans, ... peoples lives. The prospect of practical robots among ...
... 19 Mass spectrometry, driven by,a broad range of ... an increasing number of applications in the clinic, according,to ... Engineering and Biotechnology,News (GEN) ( http://www.genengnews.com ). Mass spec ... to a growing focus on screening patients through,the identification ...
Cached Biology Technology:Kosan Appoints Pamela S. Cohen, M.D., as Chief Medical Officer 2Kosan Appoints Pamela S. Cohen, M.D., as Chief Medical Officer 3Kosan Appoints Pamela S. Cohen, M.D., as Chief Medical Officer 4Robots moving closer to humans 2Genetic Engineering and Biotechnology News (GEN) Reports on Mass Spec in Drug Discovery 2
(Date:5/21/2013)... charted the path of insulin action in cells in ... blueprint for understanding what goes wrong in diabetes. ... Professor David James from Sydney,s Garvan Institute of Medical ... of the prestigious journal Cell Metabolism . , ... very important role in the body because it helps ...
(Date:5/20/2013)... also commonly resistant to antimicrobial substances made by ... mBio , the online open-access journal of ... and host antimicrobials LL-37 and lysozyme, which help ... that patients with life-threatening multi-drug resistant infections are ... is a last-line drug for treating several kinds ...
(Date:5/20/2013)... popularly known as the lungs of the planet, inhales carbon ... the air to grow parts that eventually fall to the ... plentiful rainfall. , Until recently people believed much of ... ended up deep in the ocean. University of Washington research ... carbon dioxide though left open the question of how ...
Breaking Biology News(10 mins):Insight into the dazzling impact of insulin in cells 2Insight into the dazzling impact of insulin in cells 3Resistance to last-line antibiotic makes bacteria resistant to immune system 2Resistance to last-line antibiotic makes bacteria resistant to immune system 3Amazon River exhales virtually all carbon taken up by rain forest 2Amazon River exhales virtually all carbon taken up by rain forest 3
... TGen Drug Development (TD2) and the Institut ... will enable both to maximize their worldwide contributions ... The partnership between TD2, a Scottsdale subsidiary of ... Marseille, France-based IPC,s comprehensive cancer center will enable ...
... University Medical Center in New York have confirmed that ... not a descendant of healthy humans dwarfed by disease. ... specimen, researchers determined the "hobbit" to be a distinct species ... Details of the study appear in the December issue of ...
... a step toward using human saliva to tell whether those ... are normal or red flags for disease, scientists are describing ... age. The discovery could lead to a simple, noninvasive test ... they suggest in a report in ACS, Journal of ...
Cached Biology News:TGen Drug Development establishes European footprint 2'Hobbits' are a new human species -- according to the statistical analysis of fossils 2
Glutamate Receptor 5/1a...
Ly-49C and Ly-49I Biotin Anti-Mouse clone 5E6, Isotype Mouse IgG 2a , kappa, 0.1 mg Consult technical datasheet for details....
Mouse monoclonal [M7-PB-E9] to pan alpha Sodium Potassium ATPase ( Abpromise for all tested applications)....
Gentamicin sulfate, 5g...
Biology Products: